The Outlook for Pharmaceuticals in South East Asia

Date: August 31, 2012
Price:
US$ 4,680.00
License [?]:
Publisher: Espicom Business Intelligence
Delivery: E-mail Delivery (PDF), Online Subscription
ID: O62C190F651EN
Leaflet:

Download PDF Leaflet

The Outlook for Pharmaceuticals in South East Asia
The eight pharmaceutical markets of South East Asia are developing at markedly different speeds and are characterised by contrasting macroeconomic factors. These markets are projected to have a combined pharmaceutical market value of US$80 billion at retail prices in 2017.

Established…

South Korea is the largest market in this region and the fourth largest in the Asia Pacific region. Other advanced markets such as Taiwan and Singapore are both relatively small, with growth limited by the size of these island nations. These three countries have a high percentage of population over 65, a growing incidence of lifestyle diseases and large health expenditures, which present many opportunities for pharmaceutical companies. However, their governments are increasingly employing protectionist measures that deter foreign companies. The biological sectors in these markets are witnessing rapid growth due to advanced technology capabilities, extensive R&D operations and strong government support.

Emergent…

Indonesia, Thailand and the Philippines are fairly large emergent pharmaceutical markets, with large populations and steadily growing economies. Despite concerns over counterfeiting and low efficacy of generic products, IPR protection and manufacturing standards are improving thanks to effective national regulations, foreign investment and joint-ventures with multinational companies. Malaysia and Vietnam are small pharmaceutical markets, typified by rapid economic growth, increasing foreign investment and support from national government. These five markets have significant OTC sectors and rapidly expanding generic sectors, and present previously untapped populations for potential foreign pharmaceutical companies.

Complete analysis to keep you informed

Now you can easily evaluate these markets with The Outlook for Pharmaceuticals in South East Asia. Each report provides individual and highly-detailed analysis of the market, looking at the key regulatory, political, economic and corporate developments in the wider context of market structure, service and access. The reports are available individually, or as a discounted collection, and prices include eight completely updated reports sent quarterly, together with a comprehensive statistical appendix. The reports are available individually, or as a discounted collection.

Focus on Biotechnology - A research-friendly environment...

These markets are keen to attract high value investment and have identified biotechnology and biopharmaceutical research as key areas. Their governments strongly advocate the growth of biotechnology.

Malaysia

The government has indentified biotechnology as one of the core technologies to accelerate the transformation of the country into a knowledge-based economy by the year 2020. As a result of this initiative, a number of new biopharmaceutical research companies have emerged.

Singapore

The biological sector is growing, with several large multinational companies investing over US$2.0 billion to set up biological facilities. The government is increasing its investment in biomedical sciences research over the period 2011 to 2015.

South Korea

The biological sector is witnessing rapid growth, with many local companies expanding their operations. Several significant biological joint-ventures were completed in 2011.

Taiwan

The government has been investing heavily in biotechnology research capability, which has encouraged biological sector growth. The government aims to double the annual output of the biological sector by 2013.

Highlights from the region

SINGAPORE

Espicom has reviewed its market estimates, and projects the Singaporean pharmaceutical market to exhibit a high single-digit CAGR during the forecast period, with impressive economic indicators being tempered by the limited population size. It will be the third smallest pharmaceutical market in the Asia Pacific region covered by Espicom in 2017. The volume of trade in pharmaceuticals flowing in and out of Singapore is disproportionately large compared with the size of the country, due to its status as a distribution centre. The country exports a large amount of pharmaceuticals, although the majority of this total is from re-exported goods. The balance of pharmaceutical trade remains positive. Between 2006 and 2010, the surplus in the balance of trade rose by a low single-digit CAGR. Retail medicaments and raw materials accounted for significant proportions of the trade surplus.

SOUTH KOREA

In November 2011, a free-trade agreement (FTA) between the USA and South Korea (KORUS) was approved, and came into effect in 2012. The KORUS FTA includes the phasing-out of tariffs for US drug companies, which means they should be able to increase their market access to South Korea. Also, the introduction of a patent linkage system, whereby drug companies are unable to produce and sell generic drugs until the original patent expires, is expected to result in a drop of as much as 120.0 billion Won (US$103.0 million) in drug production each year over a decade. In July 2011, the EU-Korea FTA was implemented and is expected to increase the volume and value of EU pharmaceuticals to South Korea due to an elimination of tariffs on EU exports. It also aims to ensure further strengthening of transparency in drug pricing decisions.

TAIWAN

The pharmaceutical market is projected to grow at a high single-digit CAGR in US dollar and local terms during the forecast period. This will make Taiwan the seventh largest pharmaceutical market in the Asia Pacific region, and the fourth largest in per capita terms. In 2010, there were 292 registered western-style pharmaceutical manufacturers and 130 traditional Chinese medicine (TCM) manufacturers in the country. Many multinationals are active in Taiwan, although the majority of them only have sales and marketing operations as they are deterred from establishing manufacturing operations due to the unequal drug pricing system. Taiwan is heavily dependent on the imports of retail medicaments, which represented 80.6% of the total imports in 2011. With limited pharmaceutical exports of only US$300.6 million in 2011, the balance of pharmaceutical trade will remain considerably negative and the deficit is likely to increase in the forecast period.

VIETNAM

According to a report by the Vietnam Competition Administration Department, just three multinational distributors, Zuellig Pharma, Mega Lifesciences and DKSH, dominate the Vietnamese pharmaceutical market through a complex network which enables them to control the volume, thus prices, of drugs distributed in the country. The report criticised both foreign suppliers and local importers for adopting strategies such as predatory pricing, boycotts, exclusive deals and patent pooling to block competition from new suppliers and importers. According to the report, the major distributors worked together to force out new entrants to the market, and once this was achieved the price levels of drugs were then raised. The entry of new, generic products was prevented by patent pooling.

Use these original and insightful reports to...
  • Assess future market values with our unique and regularly reviewed independent 5-year market forecasts.
  • Track the latest developments with the news service that is included for every country.
  • Understand the critical issues and drivers which are shaping the market.
  • Evaluate the environment for branded and generic operators and stay in touch with the fast growing biologic sector.
  • Shape and support business plans and decisions with reliable business data.
  • Benchmark key market performance with Espicom’s standardised data.
ANNUAL SUBSCRIPTION

8 MARKETS COVERED!

Indonesia
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam

HIGHLY DETAILED REPORT CONTENT

EXECUTIVE SUMMARY

Strategic Espicom Analysis
SWOT Analysis

KEY BACKGROUND DATA

Geographic
Political
Economic
Healthcare

INTELLECTUAL PROPERTY RIGHTS

Authority
Patent Protection
Supplementary Protection
Data Exclusivity
Enforcement

REGULATION

Authority
Marketing Registration
Marketing Authorisation
Post-Marketing
Clinical Trials
Advertising

PRICING & REIMBURSEMENT

Authority
Private Pricing
Public Pricing
Reimbursement

WHOLESALE

Overview
Associations
Wholesalers

RETAIL

Overview
Associations
Pharmacy Chains

MARKET ANALYSIS

Market Size
Reported Pharmacy Sales
Reported Hospital Sales

BIOLOGICAL MARKET FOCUS

Regulation
Reported Market Sales

GENERIC MARKET FOCUS

Regulation
Pricing & Reimbursement
Reported Market Sales

RESEARCH & DEVELOPMENT

Historical Analysis

PRODUCTION

Historical Analysis

INTERNATIONAL TRADE

Monthly Analysis, 2011-2012
Historical Analysis, 1995-2011
Annual Analysis, 2011

FOREIGN COMPETITION

Trade Promotion
Research-Based Producers
Generic Producers

LOCAL COMPETITION

Trade Promotion
Research-Based Producers
Generic Producers

METHODOLOGY

UPDATE LOG
Skip to top


Ask Your Question

The Outlook for Pharmaceuticals in South East Asia
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: